Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
A world-first pediatric mRNA cancer vaccine trial is launching in Australia that could open new possibilities for children with aggressive brain tumors. The Paedneo-Vax trial will evaluate individualized mRNA vaccines designed specifically for each child's cancer.
Southern RNA and Providence Therapeutics will support a clinical trial testing personalized mRNA cancer vaccines for children with treatment-resistant brain tumors, marking the first multi-site pediatric study of its kind.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06225700 |
Clinical Validation of Novel Malaria Diagnostic Tools for POC Point-of-Care Testing |
COMPLETED |
